key: cord-1005628-hyssas9v
authors: Mazeraud, Aurélien; Wolff, Michel; Lucas, Bruno; Sharshar, Tarek
title: Why the application of IVIG might be beneficial in patients with COVID-19 – Authors' reply
date: 2022-02-01
journal: Lancet Respir Med
DOI: 10.1016/s2213-2600(21)00550-6
sha: 59c58fa58e642cbd23c2895e750f970796a210ea
doc_id: 1005628
cord_uid: hyssas9v

nan

We thank Detlef Kindgen-Milles and colleagues for their Correspondence regarding the administration of intravenous immunoglobulin (IVIG) solutions enriched with IgM rather than solutions containing mainly IgG in patients with severe COVID-19.

In sepsis, most studies are retrospective, and the few trials addressing this condition are noncontrolled or have small cohorts. In COVID-19, no studies of good quality exist evaluating the effects of IgMenriched IVIG. The last surviving sepsis campaign did not recommend IVIG (IgM-enriched or not) for sepsis because of the low quality of evidence. Indeed, a Cochrane meta-analysis concluded that mortality was not reduced by IgM-enriched IVIG after exclusion of trials of low quality (relative risk 0·97, 95% CI 0·81-1·15; n=945). 1 Welte and colleagues, in their study, did not show that IgM-enriched IVIG reduced mortality and ventilatorfree days in patients with communityacquired pneumonia who underwent mechanically ventilation. However, a post-hoc analysis of their randomised clinical trial indicated a significant decrease in mortality in patients who had a high plasma C-reactive protein to IgM ratio at baseline. 2 This finding suggests that IgM-enriched IVIG could be beneficial in patients with relative IgM deficiency, an established risk factor for mortality in sepsis or COVID-19. 3 Furthermore, the immunological arguments for using IgM-enriched IVIG in sepsis could not be relevant in severe COVID-19. The intensity of the cytokine storm occurring in COVID-19 is lower than in sepsis, with interleukin 6 concentrations being about 30-times lower in patients with COVID-19 than in those with sepsis. 4, 5 Immunological studies have pointed out other mechanisms for the effects of severe COVID-19 than cytokine storm or hypogammaglobulinaemia, notably the role of circulating antiinterferon auto-antibodies targeting various inflammatory mediators. 6, 7 This humoral autoimmunity impairs the cellular antiviral response and has been shown to correlate with severity of Consequently, therapeutic plasma exchanges could represent a more rational approach, at least in the subset of patients with COVID-19 with auto-antibodies. 9 Finally, IVIGs, either standard or IgM-enriched, are associated with various side-effects. Our study findings showed a non-significant trend towards more thromboembolic events in patients receiving IVIGs than in those in the placebo group.

No robust clinical evidence or obvious immunological mechanisms exist for supporting the use of IgM-enriched IVIGs in patients with COVID-19, whereas its use might increase the occurrence of thromboembolic events. However, only a randomised clinical trial could evaluate the potential benefit of this approach.

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)

Gamma-globulin levels in patients with community-acquired septic shock

We declare no competing interests.